Retro Biosciences is an anti-aging biotech that got lots of attention in April of 2022 after receiving $180 million from investors. It’s based in Redwood City, CA.

Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a model with OpenAI to turn regular cells into stem cells.

Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials ...

OpenAI says it trained a new AI model called GPT-4b micro with Retro Biosciences, a longevity science startup trying to extend the human lifespan by 10 years, according to the MIT Technology Review.

But chances are that you’re not familiar with GPT-4b micro unless you’re involved in Retro Biosciences’ longevity work. The startup, which Sam Altman is an investor in, is studying ways to ...

Bezos-backed Altos Labs launched in 2022 with the aim of reversing aging by rejuvenating cells. Retro Biosciences, meanwhile, emerged that year with a focus on cellular reprogramming and ...

Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, The Financial Times reports.

OpenAI says it trained a new AI model called GPT-4b micro with Retro Biosciences, a longevity science startup trying to extend the human lifespan by 10 years, according to the MIT Technology Review.

OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan. Now ...

Retro Biosciences, a startup that aims to use AI to aid in drug development, is reportedly raising $1 billion to support its research, with investors including OpenAI, which has previously backed ...